Title Yoyo Data Sheet Spiroflut Range L2.pdf ✅

Yoyo Data Sheet- Spiroflut range Spiroflut Nasal Spray 1. Physical Parameters 2. Pricing 3. Focused Speciality 4. Focused Indications 5. TGT Drs at P1 Speciality No of Drs Active Ingredients - Fluticasone Furoate (27.5mcg) MRP - Rs 387 ENTs, CPs Allergic Rhinitis Primary Pack Size - 1 bottle Spray of 6 g (120 ENTs 8 Metered Doses) PTR - Rs 276.43 Secondary Pack Size - 10 bottle PTS - Rs 248.79 Tertiary Pack Size (shipper Qty) - 160 Shipper Cost - Rs 39806.4 CPs 2 Colour of the bottle - Milky white Bottle Benefit of Pricing- NA Flavour of the Spray - NA Technology of Brand - Latest German Technology Type of Pack - NA 6. Competition Details Brand Company Pack MRP Price/Unit FLOMIST CIPLA (FP) 100 MD 467.67 467.67 FLUTICONE FT ZYDUS CADILA (FF) 120 MD 489.40 489.40 FLOMIST F CIPLA (FF) 120 MD 514.31 514.31 FURAMIST CIPLA (FF) 120 MD 514.31 514.31 FLUTIFLO FT LUPIN (FF) 120 MD 486.60 486.60 AVAMYS GSK (FF) 120 MD 444.90 444.90 ALLEGRA SANOFI (FF) 120 MD 397.00 397.00
7. Key In clinic communication points Half-life is better in furoate i.e., 15.1 hrs as compared to propionate i.e., 7.8 hrs Relative receptor affinity is 1.7 times more than propionate which means efficacy and potency is more Onset of action is 6-8 hrs as compared to propionate which is 12hrs Fluticasone Furoate in Spiroflut has better tolerability with OD dosage as compare to propionate BID dosage i.e., 50mcg Age approval in furoate is 2 yrs. and above as compared to propionate which is 4yrs and above Plume geometry with "V" shape spray ensure best coverage of nasal mucosa to provide desire results Spiroflut-A Nasal Spray 1. Physical Parameters 2. Pricing 3. Focused Speciality 4. Focused Indications 5. TGT Drs at P1 Speciality No of Drs Active Ingredients - Fluticasone furoate 27.5mcg + Azelastine Hydrochloride 140 mcg MRP - Rs 423 ENT, Chest Moderate to Severe Allergic Rhinitis ENTs 7 Primary Pack Size - 1 bottle Spray 7 ml (70 Metered Doses) PTR - Rs 302.14 Secondary Pack Size - 10 bottle PTS - Rs 271.93 Tertiary Pack Size (shipper Qty) - 160 Shipper Cost - Rs 43508.8 Chest 3 Colour of the tablet - Milky white Bottle Benefit of Pricing- NA Flavour of the Spray - NA Technology of Brand - Latest German Technology Type of Pack - NA
6. Competition Details Brand Company Pack MRP Price/Unit DUONASE CIPLA 70 MD 534.71 534.71 AZEFLO NEW LUPIN 70 MD 507.85 507.85 FURAMIST AZ CIPLA 70 MD 527.45 527.45 NAZOMAC AF MACLEODS 120 MD 362.00 362.00 FLORESP AZ ZUVENTUS 70 MD 472.90 472.90 ALLEGRA DUO SANOFI 70 MD 481.00 481.00 7. Key In clinic communication points Technologically advanced device with German technology 2-shutoff valve technique that ensure accurate dosage and no priming 2-Micron filter - Ensure germ free chamber Tamper proof spray - Single assembly device ensure no contamination in drug chamber Spray pattern assured fine mist with better absorption of drug in entire nasal mucosa and no formation of droplets Plume geometry with "V" shape spray ensure best coverage of nasal mucosa to provide desire results
Allergic Rhinitis: 1. Allergic rhinitis (hay fever) is an allergic reaction to tiny particles in the air called allergens. 2. Allergic rhinitis is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhoea, and nasal pruritis (itching). 3. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase (EAR), with a subsequent leukotriene-mediated late phase-(LAR). (IgE- immunoglobulin type E) Ideal treatment approach involves – Manage immediate phase of allergy - Control allergic reaction due to histamine release - so need an antihistaminic H1RA ( Fexofenadine, levocetirizine, bilastine etc. Manage Late Phase which is leukotriene mediated- LTRA (Montelukast) Manage the nasal Inflammation, itching & nasal discharge- Corticosteroids ARIA – ALLERGIC RHINITIS & ITS IMPACT ON ASTHMA The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative develops internationally applicable guidelines for allergic respiratory diseases. The body that defines the treatment guidelines in the management of AR Classification of AR as per ARIA 1. “Intermittent” means symptoms are present: i) Less than 4 days a week ii) Or for less than 4 weeks 2. “Persistent” means symptoms are present: i) More than 4 days a week ii) And for more than 4 weeks 3. “Mild” means that none of the following items are present: i) Sleep disturbance ii) Impairment of daily activities, leisure, sport iii) Impairment of school or work iv) Troublesome symptoms 4. “Moderate-severe” means that one or more of the following items are present: i) Sleep disturbance ii) Impairment of daily activities, leisure, sport iii) Impairment of school or work iv) Troublesome symptoms Treatment approach: In Mild Persistent & Mild Intermittent AR combination of H1RA & LTRA. In Moderate to severe – Asthma Apart from oral medication since symptoms severity is more INCS are recommended as monotherapy or in combination with anti-histaminic .